Efficacy and Safety of Combination Antiplatelet Therapies in Patients With Symptomatic Intracranial Atherosclerotic Stenosis
Author(s) -
Sun U. Kwon,
KeunSik Hong,
DongWha Kang,
JongMoo Park,
Ju-Hun Lee,
YongJin Cho,
KyungHo Yu,
Ja-Seong Koo,
Ka Sing Wong,
SeungHoon Lee,
Kyung Bok Lee,
DongEog Kim,
Sang-Wook Jeong,
HeeJoon Bae,
ByungChul Lee,
MoonKu Han,
JoungHo Rha,
Hahn Young Kim,
Vincent Mok,
Yong-Seok Lee,
GyeongMoon Kim,
Nijasri C. Suwanwela,
SungCheol Yun,
Hyun-Wook Nah,
Jong S. Kim
Publication year - 2011
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.110.609370
Subject(s) - cilostazol , medicine , clopidogrel , aspirin , stroke (engine) , stenosis , cardiology , clinical endpoint , randomized controlled trial , mechanical engineering , engineering
An optimal strategy for management of symptomatic intracranial atherosclerotic stenosis (ICAS) has not yet been established. We compared the efficacy of 2 combinations of antiplatelets, aspirin plus cilostazol (cilostazol group) verus aspirin plus clopidogrel (clopidogrel group), on the progression of ICAS, which is known to be associated with clinical stroke recurrence.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom